Cited by 406Ovarian cancer diagnosis and treatmentCancer Cells and MetastasisOvarian function and disorders

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Open access

Beaufort, Corine M., Helmijr, Jean C. A., Piskorz, Anna M., Hoogstraat, Marlous, Ruigrok-Ritstier, Kirsten, Besselink, Nicolle, Murtaza, Muhammed, van IJcken, Wilfred F. J., Heine, Anouk A. J., Smid, Marcel, Koudijs, Marco J., Brenton, James D., Berns, Els M. J. J., Helleman, Jozien·2014·PLoS ONE

DOI 10.1371/journal.pone.0103988PMC PMC4167545

Open this paper in CoChat — free account Open PDF

Abstract

Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0103988

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Integrative genomics viewer
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 1×
“Sequence analysis and variant verification was performed as described previously [26,27].”
Method
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“analysed genomic data for 47 ovarian cancer cell lines from the CCLE collection [13] for genetic similarity to highgrade serous ovarian carcinomas from the TCGA data [4,57].”
Background
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
The Massachusetts Institute of Technology
Endowed, S. C. F. (1999) · Anthropology News · doi:10.1111/an.1999.40.2.6 · Cited by 3,132
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
Background
One Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice23
Fogh, J., Fogh, J. M., & Orfeo, T. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/59.1.221 · Cited by 1,599
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484 · cited 1×
“The remaining histiotypes are mucinous, endometrioid and clear cell [3].”
Background
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458 · cited 7×
“We used the expression data for 267 malignant ovarian carcinomas (GSE9891) [11] to determine the clinical significance of the morphological subtypes seen in our cell lines.”
BackgroundMethodInfluential

Flagged first, then by citations

Show all 89 references

Sorted by citations

Items 101–200 of 406

The Interplay Between Epithelial-Mesenchymal Transition (EMT) and the Thyroid Hormones-αvβ3 Axis in Ovarian Cancer
Weingarten, C., Jenudi, Y., Tshuva, R. Y., Moskovich, D., Alfandari, A., Hercbergs, A. A., Davis, P. J., Ellis, M. H., & Ashur‐Fabian, O. (2017) · Hormones and Cancer · doi:10.1007/s12672-017-0316-3 · Cited by 35
Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer
Burston, H. E., Kent, O. A., Communal, L., Udaskin, M. L., Sun, R., Brown, K. R., Jung, E., Francis, K. E., Rose, J. L., Lowitz, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142677 · Cited by 35
“…1 clear cell, and 4 of unknown histotype based on the suitability scores described by Medrano et al. (11), Marcotte et al. (12), Domcke et al. (13), and Beaufort et al. (14) (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI142677DS1).”
BackgroundInfluential
Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer
Schumann, C., Chan, S., Khalimonchuk, O., Khal, S., Moskal, V., Shah, V. M., Alani, A. W. G., Taratula, O. R., & Taratula, O. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00205 · Cited by 36
Mathematical models of breast and ovarian cancers
Botesteanu, D., Lipkowitz, S., Lee, J., & Levy, D. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1343 · Cited by 34
“No such description of in vivo cancer-cell kinetics has been described to date, and the clinical relevance of ovarian cancer cell lines remains an issue subject to further exploration.(137)”
Background
Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer
Eetezadi, S., Evans, J. C., Shen, Y.-T., Souza, R. D., Piquette‐Miller, M., & Allen, C. J. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00843 · Cited by 34
Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8
Tudrej, P., Olbryt, M., Zembala‐Nożyńska, E., Kujawa, K. A., Cortez, A. J., Fiszer-Kierzkowska, A., Pigłowski, W., Nikiel, B., Głowala‐Kosińska, M., Bartkowska‐Chrobok, A., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072080 · Cited by 34
“A2780 cells (E) have round-shaped morphology (according to [10]), while ES2 cells (H) have spindle-shaped morphology [10].”
BackgroundResultInfluential
Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6
Donato, M. D., Righino, B., Filippetti, F., Battaglia, A., Petrillo, M., Pirolli, D., Scambia, G., Rosa, M. C. D., & Gallo, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-34471-y · Cited by 34
Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer
Liu, S., Zou, Q., Chen, J., Yao, X., Guan, P., Liang, W., Deng, P., Lai, X., Yin, J., Chen, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145035 · Cited by 33
“30), and other published databases (31, 32).”
High-throughput 3-dimensional Culture of Epithelial Ovarian Cancer Cells as Preclinical Model of Disease
Heredia-Soto, V., Redondo, A., Berjón, A., Miguel-Martín, M., Díaz, E., Crespo, R., Hernández, A., Yébenes, L., Gallego, A., Feliu, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25098 · Cited by 33
Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming
Diep, C. H., Knutson, T. P., & Lange, C. A. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0431 · Cited by 33
“We selected ES-2 cells due to their inherent aggressive nature and rapid growth rate (54), low endogenous PR mRNA levels (21), andmolecular and genomic characteristics that are similar to primary tumors of high-grade serous ovarian carcinomas (the most common cancer of the ovary; ref.”
Background
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells
Faddaoui, A., Sheta, R., Bachvarova, M., Plante, M., Gregoire, J., Renaud, M., Sebastianelli, A., Gobeil, S., Morin, C., Ghani, K., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1295181 · Cited by 33
“Indeed, the SKOV3 cell line has been morphologically categorized as either mesenchymal or epithelial cell line(64) and the A2780s cell line has been characterized with intermediate (round) cellular phenotype.(64) In our hands, the SKOV3 line displayed a typical spindle-like morphology and predominant expression of mes…”
Background
Functional balance between Tcf21–Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines
Varankar, S., Kamble, S. C., Mali, A. M., More, M., Abraham, A., Kumar, B., Pansare, K., Narayanan, N. J., Sen, A., Dhake, R. D., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz119 · Cited by 32
“Ovarian cancer cell lines used in the study were all of the high grade serous histology (15,16).”
Background
Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer
McCabe, A., Zaheed, O., McDade, S. S., & Dean, K. A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1104514 · Cited by 33
“There exists over 100 OC cell lines, with around 70 commercially available through the American Type Culture Collection (ATCC), European Collection of Authenticated Cell Cultures (ECACC), Rikagaku Kenkyusho (Institute of Physical and Chemical Research, RIKEN), Leibniz Institute DSMZ, CellBank Australia (CBA) and/or th…”
BackgroundResultInfluential
Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression
Shin, H., Yang, W., Lee, E.-J., Han, G. H., Cho, H., Chay, D. B., & Kim, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205297 · Cited by 33
Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells
Altman, M. K., Alshamrani, A. A., Jia, W. P., Nguyen, H. T., Fambrough, J. M., Tran, S. K., Patel, M. B., Hoseinzadeh, P., Beedle, A. M., & Murph, M. M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.012 · Cited by 31
Mechanism of Cepharanthine Cytotoxicity in Human Ovarian Cancer Cells
Payon, V., Kongsaden, C., Ketchart, W., Mutirangura, A., & Wonganan, P. (2018) · Planta Medica · doi:10.1055/a-0706-7503 · Cited by 32
“It was reported that both CaOV-3 and OVCAR-3 ovarian cancer cell lines contain p53 mutation [23], but oncogenic mutations in the PI3K/AKT pathway are only detected in OVCAR-3 cells [24].”
Background
Sevoflurane and Desflurane Exposure Enhanced Cell Proliferation and Migration in Ovarian Cancer Cells via miR-210 and miR-138 Downregulation
Ishikawa, M., Iwasaki, M., Zhao, H., Saito, J., Hu, C., Sun, Q., Sakamoto, A., & Ma, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041826 · Cited by 32
“Furthermore, SKOV3 unlikely represents the most common ovarian cancer cell type of high-grade serous carcinoma (HGSC) [52,53] and each of the ovarian cancer cell phenotypes have their own biological characteristics.”
Background
Improving SERS biosensors for the analysis of ovarian cancer-derived small extracellular vesicles
Ngo, C. H. L., Zhang, W., Hnit, S. S. T., & Wang, Y. (2023) · The Analyst · doi:10.1039/d3an00398a · Cited by 31
Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers
Page, C. L., Amuzu, S., Rahimi, K., Gotlieb, W. H., Ragoussis, J., & Tonin, P. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.005 · Cited by 30
TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression
Park, G. B., & Kim, D. (2017) · Oncology Reports · doi:10.3892/or.2017.5941 · Cited by 30
Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin
Schumann, C., Chan, S., Millar, J. A., Bortnyak, Y., Carey, K., Fedchyk, A., Wong, L., Korzun, T., Moses, A. S., Lorenz, A. S., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.03.005 · Cited by 30
Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
Gomez, M. K., Illuzzi, G., Colomer, C., Churchman, M., Hollis, R. L., O’Connor, M. J., Gourley, C., Leo, E., & Melton, D. W. (2020) · Cancers · doi:10.3390/cancers12061503 · Cited by 33
“From our panel of validated HGSOC cell lines [39,40], ES-2 (HRR-proficient) and OVCAR8 (HRR-deficient due to hypermethylation of the BRCA1 gene promoter [41]) were chosen for the isolation of olaparib-resistant clones because of their good colony forming ability when seeded thinly.”
Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation
Lee, Y. K., Lim, J., Yoon, S. Y., Joo, J. C., Park, S.-J., & Park, Y. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102443 · Cited by 28
“Six ovarian cancer cell lines (A2780, CAOV3, TOV-112D, A2780cis, OVCAR-3, SKOV-3) were classified for their cisplatin resistance, using a previous report [28].”
Method
Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing
Nagasawa, S., Ikeda, K., Horie‐Inoue, K., Sato, S., Itakura, A., Takeda, S., Hasegawa, K., & Inoue, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184330 · Cited by 27
Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
Gralewska, P., Gajek, A., Marczak, A., & Rogalska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910557 · Cited by 29
“In this study, we evaluated how treatment with metformin would affect the anti-tumor efficacy of olaparib and whether it was possible to achieve synthetic lethality in wild-type BRCA ovarian cancer cells [39,40].”
Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer
Park, S., Kim, L. K., Park, H., Kim, H. J., & Heo, T. (2022) · Oncology Reports · doi:10.3892/or.2022.8263 · Cited by 29
“The subtypes of the ovarian cancer cell lines were as follows: A2780, not specified; OVCA433, serous; SKOV3, serous; and TOV112D, endometrioid (25).”
Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity
Chovatiya, N., Kaur, K., Huerta‐Yépez, S., Chen, P.-C., Neal, A. S., DiBernardo, G., Gumrukcu, S., Memarzadeh, S., & Jewett, A. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03192-7 · Cited by 28
“Despite the administration of treatments including systemic platinum-based chemotherapy and surgery, mortality rates for ovarian cancer have not changed in recent decades [1].”
Background
Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells
Abdalbari, F. H., Martinez-Jaramillo, E., Forgie, B. N., Tran, E., Zorychta, E., Goyeneche, A. A., Sabri, S., & Telleria, C. M. (2023) · Cancers · doi:10.3390/cancers15215136 · Cited by 28
“…during disease progression, in which PEO1 cells contain a BRCA2 germline mutation, whereas PEO4 cells have a restored version of the gene [28,62]. with HSP90 inhibitors [63], but our results showed cytotoxicity by auranoﬁn These provide a valuable model of cellular changes during disease…”
Background
In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance
Berkel, Ç., & Çaçan, E. (2020) · Cell Biology International · doi:10.1002/cbin.11352 · Cited by 27
“…incubator with 5% carbon dioxide at 37°C. Cell lines have the following characteristics: OV2008 (heterozygous for PIK3CA p.Glu545Lys (c.1633G>A; Takenaka et al., 2015), A2780 (ATM p.Pro604Ser [c.1810C>T], PTEN p.Lys128_Arg130del [c.383_391del9]; Anglesio et al., 2013; Beaufort et al., 2014).”
Background
Cysteine Boosts Fitness Under Hypoxia-Mimicked Conditions in Ovarian Cancer by Metabolic Reprogramming
Nunes, S. C., Ramos, C., Santos, I. P., Mendes, C., SILVA, F. A. B. N. D., Vicente, J. B., Pereira, S. A., Félix, A., Gonçalves, L. G., & Serpa, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722412 · Cited by 28
Harnessing preclinical models for the interrogation of ovarian cancer
Qin, T., Fan, J., Lu, F., Zhang, L., Liu, C., Xiong, Q., Zhao, Y., Chen, G., & Sun, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02486-z · Cited by 30
Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer
Kreuzinger, C., Gamperl, M., Wolf, A., Heinze, G., Geroldinger, A., Lambrechts, D., Boeckx, B., Smeets, D., Horvat, R., Aust, S., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.040 · Cited by 26
Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer
Shinderman‐Maman, E., Cohen, K., Moskovich, D., Hercbergs, A. H., Werner, H., Davis, P. J., Ellis, M. H., & Ashur‐Fabian, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-16593-x · Cited by 27
High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors
Shaw, S. K., Schreiber, C. L., Roland, F. M., Battles, P. M., Brennan, S. P., Padanilam, S. J., & Smith, B. D. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.007 · Cited by 26
Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells
Novohradský, V., Zajac, J., Vrána, O., Kašpárková, J., & Brabec, V. (2018) · Oncotarget · doi:10.18632/oncotarget.25466 · Cited by 26
“The human breast carcinoma MDAMB-231 cell line (derived from the metastatic site [59, 60] expressing wild type BRCA1 and BRCA2 [62–64, 67]) was obtained from ATCC (University Blvd. Manassas, USA).”
MethodInfluential
Mitochondrial membrane depolarization enhances TRAIL-induced cell death in adult human granulosa tumor cells, KGN, through inhibition of BIRC5
MacDonald, J. A., Kura, N., Sussman, C., & Woods, D. C. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0463-3 · Cited by 26
Folic Acid–Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting
Marverti, G., Marraccini, C., Martello, A., D’Arca, D., Pacifico, S., Guerrini, R., Spyrakis, F., Gozzi, G., Lauriola, A., Santucci, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02107 · Cited by 26
CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents
Oyama, Y., Shigeta, S., Tokunaga, H., Tsuji, K., Ishibashi, M., Shibuya, Y., Shimada, M., Yasuda, J., & Yaegashi, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251079 · Cited by 24
Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers
Singh, T., Neal, A. S., DiBernardo, G., Raheseparian, N., Moatamed, N. A., & Memarzadeh, S. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5325 · Cited by 26
Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer
Mize, B. K., Salvi, A., Ren, Y., Burdette, J. E., & Fuchs, J. R. (2023) · Natural Product Reports · doi:10.1039/d2np00091a · Cited by 27
Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer
Li, S., Cao, J., Zhang, W., Zhang, F., Ni, G., Luo, Q., Wang, M., Tao, X., & Xia, H. (2016) · Scientific Reports · doi:10.1038/srep36873 · Cited by 25
“…factors associated with both cisplatin and doxorubicin resistance in ovarian cancer, we compared the gene expression differences in A2780, A2780CIS and A2780ADR cells obtained from the European Collection of Cell Cultures (ECACC) using ovarian cancer cell line panel gene expression data 7 .”
Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells
Moffitt, L. R., Bilandzic, M., Wilson, A. L., Chen, Y., Gorrell, M. D., Oehler, M. K., Plebanski, M., & Stephens, A. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218110 · Cited by 25
Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells
Harmych, S. J., Kumar, J. P., Bouni, M. E., & Chadee, D. N. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112167 · Cited by 25
On the Mechanism of Hyperthermia-Induced BRCA2 Protein Degradation
van den Tempel, N., Zelensky, A. N., Odijk, H., Laffeber, C., Schmidt, C. K., Brandsma, I., Demmers, J., Krawczyk, P. M., & Kanaar, R. (2019) · Cancers · doi:10.3390/cancers11010097 · Cited by 25
“Helleman of the Department of Medical Oncology of the Erasmus University Medical Center, and cultured as described [95].”
Method
Understanding the effect of mechanical forces on ovarian cancer progression
Martinez, A., Buckley, M., Scalise, C. B., Katre, A. A., Dholakia, J., Crossman, D. K., Birrer, M. J., Berry, J. L., & Arend, R. C. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.003 · Cited by 26
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas
Thu, K. L., Papari-Zareei, M., Stastny, V., Song, K., Peyton, M., Martínez, V. D., Zhang, Y.-A., Castro, I. B., Varella‐Garcia, M., Liang, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9929 · Cited by 24
“com/oncotarget and/or contamination, lack of resemblance to clinical tumors, lack of molecular characterization, and lack of availability of the most suitable models [6-8, 15-18, 32, 33].”
Method
VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation
Shathasivam, P., Kollara, A., Spybey, T., Park, S., Clarke, B. A., Ringuette, M. J., & Brown, T. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.51 · Cited by 24
“In addition, ES-2 cells have an activating V600E mutation in BRAF (Estep et al, 2007), whereas SKOV3 cells have mutations in ARID1A and PIK3CA (Kang et al, 2005; Domcke et al, 2013; Beaufort et al, 2014), which are more prevalent in endometrioid and clear cell histotypes.”
Background
The 1,10-Phenanthroline Ligand Enhances the Antiproliferative Activity of DNA-Intercalating Thiourea-Pd(II) and -Pt(II) Complexes Against Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cell Lines
Marverti, G., Gozzi, G., Lauriola, A., Ponterini, G., Belluti, S., Imbriano, C., Costi, M. P., & D’Arca, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246122 · Cited by 23
A biomimetic model of 3D fluid extracellular macromolecular crowding microenvironment fine-tunes ovarian cancer cells dissemination phenotype
Bascetin, R., Laurent-Issartel, C., Blanc‐Fournier, C., Vendrely, C., Kellouche, S., Carreiras, F., Gallet, O., & Leroy‐Dudal, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120610 · Cited by 23
PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway
Elsayed, A. M., Bayraktar, E., Amero, P., Salama, S. A., Abdel‐Aziz, A. H., Ismail, R. S., Zhang, X., Ivan, C., Sood, A. K., Lopez‐Berestein, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041882 · Cited by 23
“SKOV3 cells harbor an amplifying mutation for PIK3CA, whereas A2780 is characterized by loss of PTEN function [36].”
Background
The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro
Amanda, M., Dave, F., Pados, G., Tsolakidis, D., Gidron, Y., Pang, Y., Thomas, P., Hall, M., & Karteris, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3410 · Cited by 23
“SkOv3 have mutations in TP53 and PIk3CA genes, whereas MDAH2774 have mutations in TP53, PIk3CA, kRAS, BRCA1 (silent) and BRCA2 (silent) (53).”
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines
Nakachi, I., Helfrich, B., Spillman, M., Mickler, E. A., Olson, C., Rice, J., Coldren, C. D., Heasley, L., Geraci, M. W., & Stearman, R. S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12413 · Cited by 23
Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
Chui, M. H., Doodnauth, S. A., Erdmann, N., Tiedemann, R. E., Sircoulomb, F., Drapkin, R., Shaw, P. H., & Rottapel, R. K. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3029 · Cited by 23
“Notably, we observed that TP53-wildtype ovarian cancer cell lines A2780 and TOV21G cells, likely derived from endometrioid and clear cell carcinoma, respectively (28, 29), were particularly sensitive to chromosome missegregation.”
Background
The Capacity of High-Grade Serous Ovarian Cancer Cells to Form Multicellular Structures Spontaneously along Disease Progression Correlates with Their Orthotopic Tumorigenicity in Immunosuppressed Mice
Goyeneche, A. A., Lisio, M. A., Fu, L., Srinivasan, R., Capuccino, J. V., Gao, Z., & Telleria, C. M. (2020) · Cancers · doi:10.3390/cancers12030699 · Cited by 23
“disease development when using certain types of high-grade serous cells, such as the case of PEO4 and PEO6 cells representing advanced disease [13,56].”
Background
Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators
Moyle-Heyrman, G., Schipma, M. J., Dean, M., Davis, D. A., & Burdette, J. E. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0213-3 · Cited by 22
“Two other estrogen responsive OVCA cell lines, PEO1 and PEO4, have recently been reported as HGSC [55].”
Background
Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
Koc, Z. C., Sollars, V. E., Zgheib, N. B., Rankin, G. O., & Koc, E. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1129352 · Cited by 22
“Among these cell lines, OVCAR-3 and OVCAR-4 are the closest cell line models to HGSOC by comparing the genomic profiles (51, 52).”
Background
Knockdown of heat shock protein family D member 1 (HSPD1) promotes proliferation and migration of ovarian cancer cells via disrupting the stability of mitochondrial 3-oxoacyl-ACP synthase (OXSM)
Duan, Y., Yu, J., Chen, M., Lu, Q., Ning, F., Gan, X., Liu, H., Ye, Y., Lu, S., & Lash, G. E. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01156-8 · Cited by 22
“A2780, TOV21G and ES2 originated from tumor tissue [53].”
Background
Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target
Saed, G. M., Fletcher, N. M., Diamond, M. P., Morris, R. T., Gomez‐Lopez, N., & Memaj, I. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.12.018 · Cited by 22
Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade
Natoli, M., Bonito, N. A., Robinson, J. D., Ghaem‐Maghami, S., & Mao, Y. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02544-5 · Cited by 22
“4d) and the PEO1/PEO4 (Fig.”
Result
E2F8 Induces Cell Proliferation and Invasion through the Epithelial–Mesenchymal Transition and Notch Signaling Pathways in Ovarian Cancer
Eoh, K. J., Kim, H. J., Lee, J. W., Kim, L. K., Park, S., Kim, H. S., Kim, Y. T., & Koo, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165813 · Cited by 23
TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells
Anbalagan, S., Ström, C. E., Downs, J. A., Jeggo, P. A., McBay, D., Wilkins, A. C., Rothkamm, K., Harrington, K. J., Yarnold, J. R., & Somaiah, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-86681-6 · Cited by 23
CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors
Xu, Z., Vandenberg, C. J., Lieschke, E., Rago, L. D., Scott, C. L., & Majewski, I. J. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0791 · Cited by 22
Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer
Samec, T., Alatise, K. L., Boulos, J., Gilmore, S. N., Hazelton, A., Coffin, C., & Alexander-Bryant, A. A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.012 · Cited by 21
“The cell line used in this study, OVCAR3, was selected because of its clinical relevance to high-grade serous ovarian adenocarcinoma in addition to its use in our in vitro work.(55,56) However, this cell line has had difficulty developing xeno-”
Method
Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer
Jin, J., Xiang, W., Wu, S., Wang, M., Xiao, M., & Deng, A. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.117 · Cited by 21
CD34 + progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg null mice
der Meer, J. M. R. V., de Jonge, P. K. J. D., van der Waart, A. B., Geerlings, A. C., Moonen, J. P., Brummelman, J., de Klein, J., Vermeulen, M. C., Maas, R. J. A., Schaap, N. P., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1981049 · Cited by 21
“This is in contrast to another study showing that OVCAR-3 was most sensitive to gemcitabine, followed by IGROV-1 and SKOV-3.(29) This difference might be attributed to different incubation times (48 h in our study vs 5 days in the other study) or other differences in experimental conditions.”
Result
Shift in MSL1 alternative polyadenylation in response to DNA damage protects cancer cells from chemotherapeutic agent-induced apoptosis
Kunisky, A. K., Anyaeche, V. I., Herron, R. S., Park, C. Y., & Hwang, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109815 · Cited by 23
“Therefore, we chose A2780cis cells, an ovarian cancer cell line with cisplatin resistance (Beaufort et al., 2014), to test for possible beneficial effects from MSL1 knockdown on cisplatin treatment.”
Background
Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis
Collins, K. E., Wang, X., Klymenko, Y., Davis, N. B., Martinez, M. C., Zhang, C., So, K., Buechlein, A. M., Rusch, D. B., Creighton, C. J., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1162786 · Cited by 21
Enhanced Accumulation of Cisplatin in Ovarian Cancer Cells from Combination with Wedelolactone and Resulting Inhibition of Multiple Epigenetic Drivers
Sarwar, S., Alamro, A. A., Alghamdi, A. A., Naeem, K., Ullah, S., Arif, M., Yu, J., & Huq, F. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s288707 · Cited by 20
“The results show that the combination was nearly additive (for more details interested readers may consult reference 24 where explanation is provided in supplementary Table 1) for all the sequences of administration in cisplatin-resistant cell line A2780cisR.”
BackgroundInfluential
Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells
Decollogne, S., Joshi, S. M., Chung, S. A., Luk, P. P., Yeo, R. X., Nixdorf, S., Fedier, A., Heinzelmann-Schwarz, V. A., Hogg, P. J., & Dilda, P. J. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.018 · Cited by 20
BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines
Shen, Y. T., Evans, J. C., Zafarana, G., Allen, C. J., & Piquette‐Miller, M. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00246 · Cited by 20
Pharmacological inhibition of BAD Ser99 phosphorylation enhances the efficacy of cisplatin in ovarian cancer by inhibition of cancer stem cell-like behavior
Wang, Y., Chiou, Y.-S., Chong, Q.-Y., Zhang, M., Rangappa, K. S., Ma, L., Zhu, T., Kumar, A. P., Huang, R. Y.-J., Pandey, V., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00064 · Cited by 20
Differential epithelial and stromal LGR5 expression in ovarian carcinogenesis
Kim, H., Lee, D. H., Park, E., Myung, J. K., Park, J. H., Kim, D., Kim, S. I., Lee, M., Kim, Y.-H., Park, C. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-15234-2 · Cited by 18
“Present 26 (41) 13 (50) 13 (50) 18 (69) 8 (31)”
Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing
Psilopatis, I., Sykaras, A. G., Mandrakis, G., Vrettou, K., & Theocharis, S. E. (2022) · Biomedicines · doi:10.3390/biomedicines11010001 · Cited by 20
The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
Yeo, X. H., Sundararajan, V., Wu, Z., Phua, Z. J. C., Ho, Y. Y., Peh, K. L. E., Chiu, Y.-C., Tan, T. Z., Kappei, D., Ho, Y. S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05045-0 · Cited by 21
Patient‐derived organoid culture in epithelial ovarian cancers—Techniques, applications, and future perspectives
Chan, W. S., Mo, X.-T., Ip, P. P. C., & Tse, K. Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6521 · Cited by 20
CD24 induced cellular quiescence-like state and chemoresistance in ovarian cancer cells via miR-130a/301a-dependent CDK19 downregulation
Jang, Y., Kang, S., Han, H. H., Kim, B. G., & Cho, N. H. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01858-y · Cited by 19
“Our results suggest that the CD24-miR-130a/301a-CDK19 signaling axis could be a prognostic marker for or a potential therapeutic target against ovarian cancer recurrence.”
Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines
Losi, L., Lauriola, A., Tazzioli, E., Gozzi, G., Scurani, L., D’Arca, D., & Benhattar, J. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0536-y · Cited by 19
Inhibition of miR-141 and miR-200a Increase DLC-1 and ZEB2 Expression, Enhance Migration and Invasion in Metastatic Serous Ovarian Cancer
Wahab, N. A., Othman, Z., Nasri, N. W. M., Mokhtar, M. H., Ibrahim, S. F., Hamid, A. A., Ali, R. A. R., & Mokhtar, N. M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17082766 · Cited by 19
“Both Caov3 and SKOV3 cell lines have TP53 mutations, but SKOV3 cells also have ARID1A mutation, making Caov3 putative histology as serous, while SKOV3 very much represents the endometrioid histological subtype [36].”
Background
Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3-bromopyruvate
Pieńkowska, N., Bartosz, G., Furdak, P., & Sadowska‐Bartosz, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020709 · Cited by 19
“PEO1 is a high-grade serous, and SKOV3 a non-serous, OC cell line [27,28].”
Background
Identification of Epithelial Ovarian Tumor-Specific Aptamers
Benedetto, G., Hamp, T. J., Wesselman, P. J., & Richardson, C. A. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0522 · Cited by 19
Voltage-Gated Sodium Channels as Potential Biomarkers and Therapeutic Targets for Epithelial Ovarian Cancer
Brummelhuis, I. S. G., Fiascone, S. J., Hasselblatt, K. T., Frendl, G., & Elias, K. M. (2021) · Cancers · doi:10.3390/cancers13215437 · Cited by 18
“Unfortunately, they described only one ovarian cancer cell line, and the cell line they used, SKOV3, has recently been classified as a poor ovarian cancer model [56].”
Background
Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
Neal, A. S., Lai, T. S., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D. A., Scott, P., Pellegrini, M. A., & Memarzadeh, S. (2021) · Cancers · doi:10.3390/cancers13235908 · Cited by 18
“OVCAR3 cells are known to be platinum-sensitive [26]; therefore, in these experiments, tumor-bearing mice were treated with carboplatin at a dose of 10 mg/kg IP 1×/week.”
BackgroundMethod
Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition
Subeha, M. R., Goyeneche, A. A., Bustamante, P., Lisio, M. A., Burnier, J. V., & Telleria, C. M. (2021) · Cancers · doi:10.3390/cancers14010099 · Cited by 17
“These cell lines demonstrated differential morphological and genetic patterns in vitro [19,20], and matched the genomic landscape of HGSOC [51].”
Background
Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics
Morse, D. B., Michalowski, A. M., Ceribelli, M., Jonghe, J. D., Vias, M., Riley, D., DAVIES-HILL, T. M., Voss, T. C., Pittaluga, S., Muus, C., et al. (2023) · Cell Systems · doi:10.1016/j.cels.2023.05.003 · Cited by 18
Effect of Polyplex Size on Penetration into Tumor Spheroids
Casadidio, C., Hartman, J. E. M., Mesquita, B. S., Haegebaert, R., Remaut, K., Neumann, M., Hak, J., Censi, R., Martino, P. D., Hennink, W. E., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00397 · Cited by 18
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
Kim, H. S., Sung, Y.-J., & Paik, S. (2015) · Yonsei Medical Journal · doi:10.3349/ymj.2015.56.5.1186 · Cited by 17
Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation andin vivotumor growth in a highly tumorigenic ovarian cancer model
Paris, L., Podo, F., Spadaro, F., Abalsamo, L., Pisanu, M. E., Ricci, A. L., Cecchetti, S., Altabella, L., Buoncervello, M., Lozneanu, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18992 · Cited by 18
“To this end, we used two cellbased human EOC models: 1) the at present unique commercially available human HER2-overepressing EOC cell line SKOV3 (HER2+++ , EGFR++, HER3+/−, HER4+/−, PTEN+/−, p53-null) [25] and 2) its in vivopassaged and in vitro stabilized SKOV3.”
Method
The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation
Heredia-Soto, V., López‐Guerrero, J. A., Redondo, A., & Mendiola, M. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2019.11.003 · Cited by 21
Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells
Garrido, M. P., Salvatierra, R., Valenzuela, M., Vallejos, C., Bruneau, N., Hernández, A., Vega, M., Selman, A., Quest, A. F. G., & Romero, C. (2020) · Pharmaceuticals · doi:10.3390/ph13100315 · Cited by 18
“SKOV3 cells are resistant to several cytotoxic drugs and are highly migratory and invasive [51,67], similar to metastatic cells.”
Background
Effect of progesterone and first evidence about allopregnanolone action on the progression of epithelial human ovarian cancer cell lines
Pelegrina, L. T., Sanhueza, M. D. L. Á., Cáceres, A. R. R., Cuello-Carrión, D., Rodriguez, C. E., & Laconi, M. R. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105492 · Cited by 18
H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival
Saravi, S., Katsuta, E., Jeyaneethi, J., Amin, H. A., Kaspar, M., Takabe, K., Pados, G., Drenos, F., Hall, M., & Karteris, E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092844 · Cited by 17
“This refers to EOC (up to 50% of HGS) that exhibit a defective phenotype of homologous recombination repair (HRR) without BRCA mutations [34,35].”
Background
S, N-doped carbon dots-based cisplatin delivery system in adenocarcinoma cells: Spectroscopical and computational approach
Dučić, T., Alves, C. S., Vučinić, Ž., Martínez, J. M. L., Petković, M., Soto, J., Mutavdžić, D. R., de Yuso, M. D. V. M., Radotić, K., & Algarra, M. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.05.005 · Cited by 17
The Anti-Tumor Efficacy of Verbascoside on Ovarian Cancer via Facilitating CCN1-AKT/NF-κB Pathway-Mediated M1 Macrophage Polarization
Ren, Y., He, J., Zhao, W., & Ma, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901922 · Cited by 17
“Using cell lines with different morphology and origin in this study can better confirm the therapeutic effect of VB on OC (32).”
Background
Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype
Axemaker, H., Plesselova, S., Calar, K., Jorgensen, M. M., Wollman, J. W., & de la Puente, P. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119801 · Cited by 22
Silencing of Epidermal Growth Factor-like Domain 8 Promotes Proliferation and Cancer Aggressiveness in Human Ovarian Cancer Cells by Activating ERK/MAPK Signaling Cascades
Song, Y. J., Kim, J., Rajbongshi, L., Lim, Y.-S., Ok, Y.-J., Hwang, S.-Y., Park, H.-Y., Lee, J.-E., Oh, S., Kim, B. S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010274 · Cited by 17
CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma
Kleinmanns, K., Bischof, K., Anandan, S., Popa, M. L., Akslen, L. A., Fosse, V., Karlsen, I. T., Gjertsen, B. T., Bjørge, L., & McCormack, E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102782 · Cited by 17
“Several reports have independently demonstrated that these cell lines result in greater molecular fidelity to HGSOC compared with the most commonly used cell line SKOV3and we additionally demonstrate the efficacy of the orthotopic OV-90 model in evaluation of clinical employed chemotherapeutics [20,21,53,54].”
Result
Specific Antiproliferative Properties of Proteinaceous Toxin Secretions from the Marine Annelid Eulalia sp. onto Ovarian Cancer Cells
Rodrigo, A. P., Mendes, V. M., Manadas, B. J., Grosso, A. R., Matos, A., Baptista, P. V., Costa, P. M., & Fernandes, A. R. (2021) · Marine Drugs · doi:10.3390/md19010031 · Cited by 17
“Ovarian cancer is the deadliest gynecological cancer in the world (see, for instance, [3]), in large part due to the late diagnosis [4].”
Background
Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells’ Cisplatin Resistance and EMT Markers Level
Kiełbik, M., Szulc-Kiełbik, I., & Klink, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020980 · Cited by 17
“Moreover, it is worth to mention that presented cell lines also differ in place of origin, with A2780 and A2780cis cells originating from ovary tissue, while SK-OV-3 and OVCAR-3 cells originating from ascites [31].”
Background
Mechanisms of Apoptosis-Related Long Non-coding RNAs in Ovarian Cancer
Takeiwa, T., Ikeda, K., Horie‐Inoue, K., & Inoue, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641963 · Cited by 17
The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCAMUT and BRCAWT Ovarian Cancer Cells
Gralewska, P., Gajek, A., Rybaczek, D., Marczak, A., & Rogalska, A. (2022) · Cells · doi:10.3390/cells11121889 · Cited by 17
“High-grade serous ovarian carcinoma (HGSOC) accounts for approximately 50% of ovarian cancers and is characterized by TP53 mutations (96%), homologous recombination (HR) DNA repair defects (50%), cyclin E1 (CCNE1) amplification and genomic instability [2].”
Background

Authors: Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., Koudijs, M. J., Brenton, J. D., Berns, E. M. J. J., & Helleman, J.
Affiliations: Erasmus MC Cancer Institute (NL)
University of Cambridge (GB)
University Medical Center Utrecht (NL)
Corresponding author: Berns, Els M. J. J.
ORCID: Helmijr, Jean C. A.
Piskorz, Anna M.
Hoogstraat, Marlous
Besselink, Nicolle
Murtaza, Muhammed
Smid, Marcel
Brenton, James D.
Helleman, Jozien
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2014-09-17
Volume: 9
Issue: 9
Pages: e103988
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0103988
PMC: PMC4167545
OpenAlex: W2015030879
Cited by: 403
References: 89
Citations by year: 2026: 15 · 2025: 24 · 2024: 30 · 2023: 48 · 2022: 38 · 2021: 54 · 2020: 52 · 2019: 41 · 2018: 27 · 2017: 28 · 2016: 25 · 2015: 21
FWCI: 29.95
Type: journal article
Language: en
Update notices: correction (2015-03-23)
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Figshare (submittedVersion, cc-by)
RePub (Erasmus University Rotterdam) (submittedVersion)
Funders: Cancer Research UK (15601)
Universitair Medisch Centrum Utrecht
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords: epithelial ovarian cancer, ovarian cancer cell lines, morphological subtypes, high-grade serous carcinoma, low-grade serous carcinoma, tumor heterogeneity, metastasis, prognosis, drug response, preclinical models
MeSH terms: Carcinoma, Ovarian Epithelial, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks